2. Dawood F.S., Iuliano A.D., Reed C., Meltzer M.I., Shay D.K., Cheng P.Y. et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012; 12(9): 687–95.

3. Информационный бюллетень. Глобальная статистика ВИЧ. UNAIDS. 2017: 9. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_ FactSheet_ru.pdf

4. Klein M.B., Yang H., DelBalso L., Carbonneau J., Frost E., Boivin G. Viral pathogens including human metapneumovirus are the primary cause of febrile respiratory illness in HIV-infected adults receiving antiretroviral therapy. J. Infect. Dis. 2010; 201(2): 297–301.

5. Garg S., Olsen S. J., Fernandez S., Muangchana C., Rungrojcharoenkit K., Prapasiri P. et al. Seroincidence of Influenza Among HIV-infected and HIV-uninfected Men During the 2009 H1N1 Influenza Pandemic, Bangkok, Thailand. Open Forum Infect. Dis. 2014; 1(3): ofu082. Published online 2014. doi: 10.1093/ofid/ofu082

6. Cohen C., Moyes J., Tempia S., Groom M., Walaza S., Pretorius M. et al. Severe Influenza-associated Respiratory Infection in High HIV Prevalence Setting, South Africa, 2009–2011. Emerg. Infect. Dis. 2013; 19(11): 1766–74.

7. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med. 2001; 161(3): 441–6.

8. Neuzil K.M., Coffey C.S., Mitchel E.F. Jr, Griffin M.R. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J. Acquir. Immune Defic. Syndr. 2003; 34(3): 304–7.

9. Cohen C., Simonsen L., Sample J., Kang J.-W., Miller M., Madhi S. A. et al. Influenza-Related Mortality Among Adults Aged 25–54 Years With AIDS in South Africa and the United States of America. Clin. Infect. Dis. 2012; 55(7): 996–1003.

10. Cohen C., Moyes J., Tempia S., Groome M., Walaza S., Pretorius M. et al. Mortality amongst Patients with Influenza-Associated Severe Acute Respiratory Illness, South Africa, 2009–2013. PLoS One 2015; 10(3): e0118884. DOI: 10.1371/journal.pone.0118884

11. Walaza S., Cohen C., Nanoo A., Cohen A. L., McAnerney J., Mollendorf C. et al. Excess Mortality Associated with Influenza among Tuberculosis Deaths in South Africa, 1999–2009. PLoS One 2015; 10(6): e0129173. DOI: 10.1371/journal.pone.0129173

12. Golden M.P., Sajjad Z., Elgart L. Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection. Clin. Infect. Dis. 2001; 32(9): 1366–70.

13. Skiest D.J., Machala T. Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts. J. Clin. Virol. 2003; 26(3): 307–15.

14. Klein M.B., Lu Y., DelBalso L., Coté S., Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin. Infect. Dis. 2007; 45(2): 234–40.

15. Fine A.D., Bridges C.B., De Guzman A.M., Glover L., Zeller B., Wong S.J. et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin. Infect. Dis. 2001; 32(12): 1784–91.

16. Skiest D.J., Kaplan P., Machala T., Boney L., Luby J. Clinical manifestations of influenza in HIV-infected individuals. Int. J. STD AIDS 2001; 12(10): 646–50.

17. Radwan H.M., Cheeseman S.H., Lai K.K., Ellison III R.T. Influenza in human immunodeficiency virus-infected patients during the 1997–1998 influenza season. Clin. Infect. Dis. 2000; 31(2): 604–6.

18. Ormsby C.E., de la Rosa-Zamboni D., Va´zquez-Pe´rez J., Ablanedo-Terrazas Y., Vega-Barrientos R., Go´mez-Palacio M. et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS 2011; 25: 435–9.

19. Patel P., Bush T., Kojic E. M., Overton E. T., Henry K., Önen N. et al. Duration of Influenza Virus Shedding Among HIV-Infected Adults in the cART Era, 2010–2011. AIDS Res. Hum. Retroviruses 2016; 32(12): 1180–6.

20. López-Aldeguer J., Iribarren J.A., Valencia E., Barquilla E., Knobel H., Santos J. et al. Outcomes in HIV-infected patients admitted due to pandemic influenza. Enferm. Inf. Microbiol. Clin. 2012; 30(10): 608–2.

21. Peters P.J., Skarbinski J., Louie J.K., Jain S. New York City Department of Health Swine Flu Investigation Team, Roland M, Jani SG, Finelli L, Brooks JT. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1) – United States, spring and summer 2009. Clin. Infect. Dis. 2011; 52(Suppl 1): S183–8. DOI: 10.1093/cid/ciq036.

22. Kulkarni R., Kinikar A., Valvi C. Clinical profile of H1N1 positive HIV- infected children. Indian Pediatr. 2011; 48(2): 131–2.

23. Noguera-Julian A., Provens A.C., Soler-Palacín P., Espiau M., Mur A., Méndez M. et al. Pandemic influenza a (2009 H1N1) in human immunodeficiency virus-infected catalan children. Pediatr. Infect. Dis J. 2011; 30(2): 173–5.

24. Gallagher K.M., Juhasz M., Harris N.S., Teshale E.H. Predictors of influenza vaccination in HIV-infected patients in the United States, 1990–2002. J. Infect. Dis. 2007; 196(3): 339–46.

25. Центры по контролю и профилактике заболеваний. Сезонный грипп: основы гриппа. https://www.cdc.gov/flu/about/disease/index.htm

26. Saito N., Komori K., Suzuki M., Morimoto K., Kishikawa T., Yasaka T. et al. Negative impact of prior influenza vaccination on current influenza vaccination among people infected and not infected in prior season: A test-negative case-control study in Japan. Vaccine 2017; 35(4): 687–93.

27. Ho D.D. HIV-1 Viremia and influenza. Lancet 1992; 339: 1549.

28. Rosok B., Voltersvik P., Bjerknes R., Axelsson M., Haaheim L.R., Asjo B. Dynamics of HIV-1 replication following influenza vaccination of HIV individuals. Clin. Exp. Immunol .1996; 104: 203–7.

29. O’Brien W.A., Grovit-Ferbas K., Namazi A. Ovcak-Derzic S., Wang H.-J., Park J. et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86(3): 1082–9.

30. Sansonetti P., Sali M., Fabbiani M., Morandi M., Martucci R., Danesh A. et al. Immune response to influenza A(H1N1)v in HIV-infected patients. J. Infect. Dev. Ctries. 2014; 8(1): 101–9.

31. Staprans S.I., Hamilton B.L., Follansbee S.E., Elbeik T., Barbosa P., Grant R. M., et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J. Exp. Med. 1995; 182: 1727–37.

32. Fuller J.D., Craven D.E., Steger K.A., Cox N., Heeren T.C., Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin. Infect. Dis. 1999; 28(3): 541–7.

33. Gutiérrez F., Maestre A., Manuel Ramos J., Masiá M., Escolano C., Hidalgo A.M. Influenza vaccination of human immunodeficiency virus-infected patients with severe immunodepression. Impact on CD4 lymphocytes and plasma viral load. Med. Clin. (Barc). 2001; 117(11): 410–2. (In Spanish).

34. Banic S., Koren S., Tomazic J., Vidmar L., Ihan A., Poljak M. et al. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. Acta Virol. 2001; 45(1): 39–44.

35. Zanetti A.R., Amendola A., Besana S., Boschini A., Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002; 20(5): 29–32.

36. Sullivan P.S., Hanson D.L., Dworkin M.S., Jones J.L., Ward J.W. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000; 14(17): 2781–5.

37. Tasker S.A., Treanor J.J., Paxton W.B., Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1999; 131(6): 430–3.

38. Kroon F.P., Rimmelzwaan G.F., Roos M.T., Osterhaus A.D., Hamann D., Miedema F. et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998; 12(17): 217–23.

39. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C. et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010; 24(9): 31–5.

40. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A. et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24(14): 2187–92.

41. Chotirosniramit N., Sugandhavesa P., Aurpibul L., Thetket S., Kosashunhanan N., Supindham T. et al. Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand. Hum. Vaccin Immunother. 2012; 8(12): 1854–9.

42. Lau Y.F., Tang L.H., Chien L. D., Ooi E.E., Leo Y.S. Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore. Hum. Vaccin Immunother. 2017; 13(3): 551–60.

43. Rasoolinejad M., Jafari S., Montazeri M., Mohseni M., Foroughi M., Badie B. M. et al. Azad Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus. Acta Medica Iranica 2013; 51(3): 148–52.

44. Levin M. J., Song L.-Y., Fenton T., Nachman S., Patterson J., Walker R. et al. Shedding of Live Vaccine Virus, Comparative Safety, and Influenza-Specific Antibody Responses after Administration of Live Attenuated and Inactivated Trivalent Influenza Vaccines to HIV-Infected Children. Vaccine 2008; 26(33): 4210–7.

45. Evison J., Farese S., Seitz M., Uehlinger D. E., Furrer H., Mühlemann K. Randomized, Double-Blind Comparative Trial of Subunit and Virosomal Influenza Vaccines for Immunocompromised Patients. Clin. Infect. Dis. 2009; 48(10): 1402–12.

46. Nichol K.L. Booster doses of influenza vaccine. JAMA 1996; 276(23): 1857.

47. Miotti P.G., Nelson K.E., Dallabetta G.A., Farzadegan H., Margolick J., Clements M.L. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262(6): 779–83.

48. Iorio A.M., Alatri A., Francisci D., Preziosi R., Neri M., Donatelli I. et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine 1997; 15(1): 97–102.

49. Kroon F.P., van Dissel J.T., de Jong J.C., Zwinderman K., van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18(26): 3040–9.

50. Cooper C., Thorne A., Klein M., Conway B., Boivin G., Haase D. et al. Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults. PLoS One 2011; 6(3): e17758. DOI: 10.1371/journal.pone.0017758

51. Soonawala D., Rimmelzwaan G. F., Gelinck L. B., Visser L. G., Kroon F.P. Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination PLoS One 2011; 6(1): e16496. DOI: 10.1371/journal.pone.0016496-48

52. Rudnitski K., Galli A., Nozza L., Tambussi S., Di Pietro G., Pellicciotta A. et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011; 25: 177.

53. Ho J., Moir S., Wang W., Posada J. G., Gu W., Rehman M. T. et al. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS 2011; 25(3): 295–302.

54. Cooper C., Klein M., Walmsley S., Haase D., MacKinnon-Cameron D., Marty K. et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin. Trials. 2012; 13(1): 23–32.

55. Nielsen A.B., Nielsen H.S., Nielsen L., Thybo S., Kronborg G. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. Vaccine 2012; 30(49): 7067–71.

56. Pauksens K. Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine. Infect. Ecol. Epidemiol. 2013; (3). DOI: 10.3402/iee.v3i0.20766.

57. Bickel M., Lais C., Wieters I., Kroon F.P., Doerr H.W., Herrmann E. et al. Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients. Scand . J. Infect. Dis. 2014; 46(9): 656–9.

58. Crum-Cianflone N. F., Iverson E., Defang G., Blair P. J., Eberly L., Maguire J. Durability of antibody responses after receipt of the monovalent 2009 influenza a (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011; 29(17): 3183–91.

59. Glinka E. R., Smith D. M., Johns S. T. Administering Influenza Vaccine to HIV Patients: Does Timing Matter? HIV Med. 2016; 17(8): 601–4.

60. Agrati C., Gioia C., Castilletti C., Lapa D., Berno G., Puro V. Capobianchi Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients. AIDS Res. Hum. Retroviruses 2012; 28(12): 1606–16.

61. Seo Y. B., Lee J., Song J. Y., Choi H. J., Cheong H. J., Kim W. J. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine. Hum. Vaccin Immunother. 2016; 12(2): 478–84.

62. Weinberg A., Curtis D., Ning M. F., Claypool D. J., Jalbert E., Patterson J.et al. Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza. Vaccine Front Immunol. 2016; 7: 142. DOI: 10.3389/fimmu.2016.00142

63. Curtis D., Ning M.F., Armon C., Li S., Weinberg A. Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children. Vaccine 2015; 33 (38): 4790–7.

64. Tanzi E., Esposito S., Bojanin J., Amendola A., Trabattoni D., Pariani E. et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J. Med. Virol. 2006; 78(4): 440–5.

65. Kosalaraksa P., Srirompotong U., Newman R.W., Lumbiganon P., Wood J.M. Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. Vaccine 2015; 29(16): 3055–60.

66. Curtis D. J., Muresan P., Nachman S., Fenton T., Richardson K. M., Dominguez T. et al. Characterization of Functional Antibody and Memory B-Cell Responses to pH1N1 Monovalent Vaccine in HIV-Infected Children and Youth. PLoS One 2015; 10(3): e0118567. DOI: 10.1371/journal.pone.0118567

67. Madhi S.A., Dittmer S., Kuwanda L., Venter M., Cassim H., Lazarus E. et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS 2013; 27(3): 369–79.

68. Okike I.O., Yung C., Ladhani S., Oeser C., Bennett A., Doerholt K. et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. Vaccine 2011; 29(38): 6636–40.

69. Palma P., Romiti M.L., Bernardi S., Pontrelli G., Mora N., Santilli V. et al. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Biologicals 2012; 40(2): 134–9.

70. Dangor Z., Nunes M.C., Kwatra G., Lala S.G., Madhi S.A. Vaccination of HIV-infected pregnant women: implications for protection of their young infants. Trop. Dis. Travel. Med. Vaccines 2017; (3): 1. DOI: 10.1186/s40794-016-0044-7

71. Madhi S.A., Cutland C.L., Kuwanda L., Weinberg A., Hugo A., Jones S. et al. Influenza vaccination of pregnant women and protection of their infants. N. Engl. J. Med. 2014; 371: 918–31.

72. Malek A., Sager R., Kuhn P., Nicolaides K.H., Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol. 1996; 36: 248–55.

73. Boyer K.M., Papierniak C.K., Gadzala C.A., Parvin J.D., Gotoff S.P. Transplacental passage of IgG antibody to group B streptococcus serotype Ia. J. Pediatr. 1984; 104: 618–20.

74. Christensen K.K., Christensen P., Duc G., Hoger P., Kind C., Matsunaga T. et al. Correlation between serum antibody-levels against group B streptococci and gestational age in newborns. Eur. J. Pediatr. 1984; 142: 86–8.

75. Nunes M.C., Cutland C.L., Dighero B., Bate J., Jones S., Hugo A. et al. Kinetics of hemagglutination-inhibiting antibodies following maternal influenza vaccination among mothers with and those without HIV infection and their infants. J. Infect. Dis. 2015; 212: 1976–87.

76. Abzug M.J., Nachman S.A., Muresan P., Handelsman E., Watts D.H., Fenton T. et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin. Infect. Dis. 2013; 56: 1488–97.

77. Launay O., Desaint C., Durier C., Loulergue P., Duval X., Jacomet C. et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J. Infect. Dis. 2011; 204: 124–34.

78. Cooper C., Klein M., Walmsley S., Haase D., MacKinnon-Cameron D., Marty K. et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin. Trials. 2012; 13: 23–32. DOI: 10.1310/hct1301-23